CG Oncology, Inc. (NASDAQ:CGON) Given Average Rating of "Buy" by Brokerages

Shares of CG Oncology, Inc. (NASDAQ:CGON - Get Free Report) have earned a consensus rating of "Buy" from the eleven ratings firms that are covering the stock, MarketBeat reports. One analyst has rated the stock with a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $58.67.

Several equities analysts have weighed in on the company. Cantor Fitzgerald restated an "overweight" rating and set a $75.00 price objective on shares of CG Oncology in a research note on Monday, April 28th. HC Wainwright reiterated a "buy" rating and set a $75.00 target price on shares of CG Oncology in a research note on Monday, April 28th. Morgan Stanley lifted their target price on CG Oncology from $52.00 to $56.00 and gave the stock an "overweight" rating in a research note on Tuesday, June 17th. Royal Bank Of Canada lifted their target price on CG Oncology from $66.00 to $68.00 and gave the stock an "outperform" rating in a research note on Tuesday, April 29th. Finally, JPMorgan Chase & Co. initiated coverage on CG Oncology in a research note on Friday, May 2nd. They set an "overweight" rating and a $41.00 target price on the stock.

Insider Buying and Selling at CG Oncology

In other CG Oncology news, Director Leonard E. Post sold 1,000 shares of CG Oncology stock in a transaction dated Monday, April 28th. The stock was sold at an average price of $30.76, for a total transaction of $30,760.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 7.40% of the company's stock.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. GF Fund Management CO. LTD. purchased a new position in CG Oncology during the 4th quarter valued at about $41,000. CWM LLC grew its holdings in CG Oncology by 3,957.7% during the 1st quarter. CWM LLC now owns 2,110 shares of the company's stock valued at $52,000 after buying an additional 2,058 shares in the last quarter. GAMMA Investing LLC grew its holdings in CG Oncology by 1,051.0% during the 1st quarter. GAMMA Investing LLC now owns 2,302 shares of the company's stock valued at $56,000 after buying an additional 2,102 shares in the last quarter. KLP Kapitalforvaltning AS purchased a new position in CG Oncology during the 4th quarter valued at about $100,000. Finally, Federated Hermes Inc. purchased a new position in shares of CG Oncology during the fourth quarter worth about $172,000. Hedge funds and other institutional investors own 26.56% of the company's stock.

CG Oncology Stock Up 0.0%

NASDAQ:CGON traded up $0.01 during trading hours on Monday, hitting $26.07. 694,133 shares of the company traded hands, compared to its average volume of 841,208. The firm's 50-day simple moving average is $25.32 and its 200-day simple moving average is $26.35. CG Oncology has a one year low of $14.80 and a one year high of $40.47. The company has a market cap of $1.99 billion, a PE ratio of -17.26 and a beta of 0.86.

CG Oncology (NASDAQ:CGON - Get Free Report) last issued its quarterly earnings data on Tuesday, May 13th. The company reported ($0.45) earnings per share for the quarter, missing the consensus estimate of ($0.36) by ($0.09). CG Oncology had a negative net margin of 15,945.17% and a negative return on equity of 16.71%. The company had revenue of $0.05 million for the quarter, compared to the consensus estimate of $0.53 million. As a group, equities research analysts expect that CG Oncology will post -1.31 EPS for the current year.

CG Oncology Company Profile

CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.